 ValuEngine lowered shares of Akebia Therapeutics NASDAQ:AKBA from a buy rating to a hold rating in a research report released on Monday morning, ValuEngine reports. Several other brokerages also recently issued reports on AKBA. Mizuho boosted their price target on shares of Akebia Therapeutics from 15.00 to 17.00 and gave the company a buy rating ... 